NOVAVAX FINDS VACCINE 89
Novavax said two-shot of its vaccine showed an overall efficacy rate of 89%, with a high of 96% against the global variant of the virus. The efficacy dipped to 86% in the case of the B.1.1.7 variant first seen in the United Kingdom, and further to 60% in the case of the B.1.351 variant spreading in South Africa.
Whole world is fighting from covid-19 after the WHO declared it as a global a pandemic. From last January the race to develop vaccine against covid-19 was started between different organization around the globe. Novavax leading organization in developing covid-19 vaccine said that its two-shot vaccine showed an overall efficacy rate of 89%, with a high of 96% against the dominant global variant of the virus.
Novavax has joined hands with pune’s Serum Institute of India to manufacture a billion doses of novavax vaccine for low- and middle-income countries and India. Novavax likely to be available all over India if everything goes according to the plan.
Novavax said two-shot of its vaccine showed an overall efficacy rate of 89%, with a high of 96% against the global variant of the virus. The efficacy dipped to 86% in the case of the B.1.1.7 variant first seen in the United Kingdom, and further to 60% in the case of the B.1.351 variant spreading in South Africa.
Hours after the efficacy results were announced from Novavax vaccine, Serum Institute of India CEO Adar Poonawalla told Reuters that his company has applied for permission to conduct vaccine trial in India. He said, “We have already applied to the drug controller’s office for the bridging trial, a few days ago, so they should also give that approval soon now,”
SII which manufacture the world’s largest volume of vaccine every year is also making a billion doses of the Oxford-AstraZeneca vaccine, which it has supplied in millions to India, where it is the most widely used dose.
“With today’s results from our UK Phase 3 and South Africa Phase 2b clinical trials, we have now reported data on our Covid-19 vaccine from Phase 1, 2 and 3 trials involving over 20,000 participants. NVX-CoV2373 is the first vaccine to demonstrate not only high clinical efficacy against Covid but also significant clinical efficacy against both the rapidly emerging UK and South Africa variants,” said Stanley C Erck, president and chief executive officer, Novavax, according to a company statement
